From Biology to Bedside: Challenges and Strategies in Developing Combination Cancer Therapies in Early-Phase Trials

Area of Science:

• Oncology
• Clinical Trial Design
• Molecular Profiling

Background:

• Next-generation sequencing and molecular profiling have advanced cancer research, increasing targeted therapy development.
• Single-agent targeted therapies face limitations like primary/acquired resistance and compensatory alterations, leading to non-durable responses.
• Intratumoral heterogeneity and clonal evolution pose challenges to effective cancer treatment.

Purpose of the Study:

• To summarize key aspects of early-phase clinical trials for combination therapy in oncology.
• To discuss regulatory, biological, and logistical considerations for developing combination strategies.
• To propose recommendations for designing and conducting future early-phase combination trials, referencing Project Optimus.

Main Methods:

• Review of key aspects of early-phase clinical trials for combination therapy.
• Discussion of regulatory, biological, and logistical considerations.
• Analysis of recent successes and challenges in combination therapy trials.

Main Results:

• Combination strategies are essential to overcome resistance mechanisms and improve antitumor response durability.
• Biomarker integration, real-time molecular profiling, and adaptive trial infrastructure are critical for future combination trials.
• Recent clinical successes highlight the potential of combination therapies, despite ongoing challenges.

Conclusions:

• Rational combination strategies are vital for overcoming resistance and improving outcomes in oncogene-driven cancers.
• Optimizing early-phase clinical trial design, incorporating Project Optimus principles, is necessary for successful combination therapy development.
• Future research should focus on adaptive trial designs and integrated biomarkers to enhance the efficacy of combination treatments.